AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38825014
Drug: High energy
RxNorm normalized name: High energy formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy density food (>3.0 kcal/g)
Trial: 38825014
Drug: Medium energy
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium energy density food (1.7-2.0 kcal/g)
Trial: 38825014
Drug: Low energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low energy density food (∼1.0 kcal/g)
Trial: 38825333
Drug: Specialised mood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialised mood disorder clinic treatment combining evidence-based pharmacological treatment with group psychoeducation
Trial: 38825333
Drug: Specialised mood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialised mood disorder clinic treatment
Trial: 38825627
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg
Trial: 38825627
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine (T-DM1) 3.6 mg/kg
Trial: 38825627
Drug: Treatment-emergent adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent adverse events for T-DXd
Trial: 38825627
Drug: Treatment-emergent adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent adverse events for T-DM1
Trial: 38825688
Drug: Pulmonary endarterectomy
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary endarterectomy (PEA), Balloon pulmonary angioplasty (BPA), and targeted medical therapy
Trial: 38825999
Drug: Computer-based biodex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-based biodex balance exercise system (BBS) performed twice weekly for 8 weeks
Trial: 38826330
Drug: SP-2509 (noncompetitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP-2509 (noncompetitive inhibitor)
Trial: 38826570
Drug: Standard step-up
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard step-up conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)
Trial: 38826570
Drug: Combination csDMARDs
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination csDMARDs (methotrexate with either sulfasalazine or leflunomide)
Trial: 38826570
Drug: Early biologics
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early biologics induction therapy (adalimumab plus methotrexate)
Trial: 38827854
Drug: Oral Hydroxychloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Hydroxychloroquine (HC), Azithromycin (AZ), and Oseltamivir (OS)
Trial: 38828023
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg HCTZ for four days
Trial: 38828023
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg henagliflozin for four days
Trial: 38828023
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg HCTZ + 10 mg henagliflozin for four days
Trial: 38828023
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (HCTZ + henagliflozin)
Trial: 38828109
Drug: Weekly chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly chloroquine prophylaxis (CQ)
Trial: 38828563
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose edoxaban regimen (60/30 mg daily)
Trial: 38828563
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose edoxaban regimen (30/15 mg daily)
Trial: 38828938
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly paclitaxel
Trial: 38828958
Drug: IV posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV posaconazole 300 mg q12h and 300 mg q8h for the first two days, followed by 400 mg q24h maintenance
Trial: 38828958
Drug: IV posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV posaconazole 300 mg q24h
Trial: 38829011
Drug: Dual-IVT strategy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-IVT strategy with tenecteplase 0.25 mg/kg
Trial: 38829618
Drug: Remote monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remote monitoring of BP and medication adherence (RM)
Trial: 38829618
Drug: Remote monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remote monitoring of BP and medication adherence with social support (SS)
Trial: 38829703
Drug: Lademirsen, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lademirsen, dosage and duration not available
Trial: 38829882
Drug: EPO-Feeding Program
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO-Feeding Program (four weekly group-based training sessions led by healthcare professionals)
Trial: 38830735
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) administered as 1 g at skin incision, followed by an additional 1 g prior to skin closure.
Trial: 38830962
Drug: Phase 2
RxNorm normalized name: Premphase 28 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2 white kidney bean extract (WKBE HIGH) 1000 mg
Trial: 38830962
Drug: Phase 2
RxNorm normalized name: Premphase 28 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2 white kidney bean extract (WKBE LOW) 700 mg
Trial: 38830992
Drug: satri-cel monotherapy
RxNorm normalized name: Obe-cel
DrugBank: Obecabtagene autoleucel (DB17362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: satri-cel monotherapy in 61 patients with standard chemotherapy-refractory gastrointestinal cancers
Trial: 38830992
Drug: satri-cel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: satri-cel plus anti-PD-1 therapy in 15 patients with standard chemotherapy-refractory gastrointestinal cancers
Trial: 38830992
Drug: satri-cel as
RxNorm normalized name: Obe-cel
DrugBank: Obecabtagene autoleucel (DB17362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: satri-cel as sequential treatment after first-line therapy in five patients with gastrointestinal cancers
Trial: 38830992
Drug: satri-cel monotherapy
RxNorm normalized name: Obe-cel
DrugBank: Obecabtagene autoleucel (DB17362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: satri-cel monotherapy in two patients with anti-CLDN18.2 monoclonal antibody-refractory gastric cancer
Trial: 38831415
Drug: Integrated MOUD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated MOUD and HIV treatment/prevention through a mobile unit
Trial: 38832837
Drug: Dexmedetomidine infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusions
Trial: 38832837
Drug: Continuous infusions
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusions of opioids
Trial: 38832837
Drug: Continuous infusions
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusions of ketamine
Trial: 38832949
Drug: Oral THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral THC (10 mg)
Trial: 38832995
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of adenosine
Trial: 38833144
Drug: IVL3001 (12-36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVL3001 (12-36 mg)
Trial: 38833144
Drug: IVL3001 (12-36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVL3001 (12-36 mg) every 4 weeks
Trial: 38833311
Drug: Olaparib treatment
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib treatment
Trial: 38833360
Drug: Successful tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Successful tapering of immunosuppressants (IS)
Trial: 38833442
Drug: Inhaled xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled xenon during targeted temperature management (TTM) at 33°C for 24 hours
Trial: 38833560
Drug: Epinephrine dosing
RxNorm normalized name: epinephrine Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine dosing intervals less than 3 minutes
Trial: 38833590
Drug: naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg twice daily for 10 days
Trial: 38833643
Drug: Everolimus +
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus + Endocrine Therapy (ET) (10 mg orally once daily for 1 year)
Trial: 38833658
Drug: Lenvatinib 20
RxNorm normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 20 mg orally once daily plus pembrolizumab 400 mg intravenously once every 6 weeks
Trial: 38833971
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg/kg intravenously every 2 weeks)
Trial: 38834087
Drug: Mitazalimab 900
RxNorm normalized name: Mitazalimab
DrugBank: Mitazalimab (DB15225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitazalimab 900 μg/kg with mFOLFIRINOX
Trial: 38834087
Drug: Mitazalimab 450
RxNorm normalized name: Mitazalimab
DrugBank: Mitazalimab (DB15225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitazalimab 450 μg/kg with mFOLFIRINOX
Trial: 38834319
Drug: Postnatal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postnatal administration of allogeneic expanded human first trimester fetal liver MSCs (BOOST cells)
Trial: 38834319
Drug: Prenatal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal and postnatal administration of allogeneic expanded human first trimester fetal liver MSCs (BOOST cells)
Trial: 38834399
Drug: Selinexor maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor maintenance therapy
Trial: 38834399
Drug: Selinexor maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor maintenance therapy (TP53wt/pMMR EC)
Trial: 38834399
Drug: Selinexor maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor maintenance therapy (TP53wt/dMMR EC)
Trial: 38834432
Drug: HRIG (0.133
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRIG (0.133 mL/kg)
Trial: 38834744
Drug: Preoperative chemoradiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiotherapy (CRT) followed by nivolumab (240 mg) and surgery
Trial: 38834776
Drug: Personalized bacteriophage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized bacteriophage therapy (BT)
Trial: 38834776
Drug: Personalized bacteriophage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized bacteriophage therapy (BT) with concomitant antibiotics
Trial: 38835146
Drug: Digitally delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitally delivered treatment comprising exercise and patient education
Trial: 38837133
Drug: Skill-oriented, material-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skill-oriented, material-based cognitive behavioral therapy (SEKT)
Trial: 38837133
Drug: Supportive, patient-centered,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive, patient-centered, emotion-focused therapy (FEST)
Trial: 38837144
Drug: Abrocitinib, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrocitinib, 200 mg, by mouth once daily for 12 weeks
Trial: 38837707
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) levels ≤500 ng/ml
Trial: 38837707
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) levels ≤200 ng/ml
Trial: 38837825
Drug: Bronchodilator therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator therapy (specific medication not mentioned), administered twice daily for 12 weeks.
Trial: 38837825
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving placebo treatment for 12 weeks.
Trial: 38837864
Drug: Weight-tiered dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-tiered dosing of pantoprazole
Trial: 38837864
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg total body weight dosing of pantoprazole
Trial: 38837864
Drug: 1.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg/kg lean body weight dosing of pantoprazole
Trial: 38837864
Drug: FDA-recommended weight-tiered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA-recommended weight-tiered dosing of pantoprazole
Trial: 38838287
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (TKI; sunitinib or cabozantinib)
Trial: 38838477
Drug: Phoenix App
RxNorm normalized name: Phoenix dactylifera pollen
DrugBank: Phoenix dactylifera pollen (DB10950)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phoenix App + Nicotine Replacement Therapy
Trial: 38838500
Drug: Pemigatinib 13.5
RxNorm normalized name: pemigatinib 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemigatinib 13.5 mg once daily in 21-day cycles (2 weeks on, 1 week off) until disease progression or unacceptable toxicity.
Trial: 38838501
Drug: Nivolumab ±
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab ± ipilimumab combined with stereotactic radiation therapy
Trial: 38839047
Drug: Intravenous remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous remdesivir
Trial: 38839101
Drug: Peer comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer comparison antibiotic prescribing feedback (intervention group)
Trial: 38839101
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (prolonged duration prescriptions)
Trial: 38839252
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of metformin use
Trial: 38839505
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg every 3 weeks until disease progression or unacceptable toxicity
Trial: 38840086
Drug: Enhanced access
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced access to HPV vaccine + Standard CDC information
Trial: 38840086
Drug: Enhanced access
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced access to HPV vaccine + Video narratives
Trial: 38840086
Drug: Enhanced access
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced access to HPV vaccine + Written narratives
Trial: 38840166
Drug: High baseline
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High baseline CRP (>3 mg/L)
Trial: 38840210
Drug: Low inhaled
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low inhaled concentration of desflurane (0.5 MAC) combined with propofol and remifentanil
Trial: 38840210
Drug: High inhaled
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High inhaled concentration of desflurane (0.7-1.0 MAC) combined with remifentanil
Trial: 38840219
Drug: JAK inhibitors
RxNorm normalized name: Janus-associated kinase (JAK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAK inhibitors (baricitinib, n=15; tofacitinib, n=10; upadacitinib, n=10)
Trial: 38841123
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to daily Occupational Performance (CO-OP) intervention
Trial: 38841377
Drug: Reference method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference method (RM) - pill count
Trial: 38841781
Drug: Ciprofloxacin 1000
RxNorm normalized name: ciprofloxacin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 1000 mg twice daily on D1-D10 + Etoposide 200 mg on D2-D8
Trial: 38841781
Drug: Ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 750 mg twice daily on D1-D10 + Etoposide 200 mg on D2-D8
Trial: 38841799
Drug: Baseline post-bronchodilator
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline post-bronchodilator (post-BD) spirometry measures of lung function
Trial: 38842347
Drug: CLN-617 (intratumoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLN-617 (intratumoral injection of a single-chain fusion protein comprising IL2 and IL12)
Trial: 38842448
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose DOAC
Trial: 38842448
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose DOAC
Trial: 38842448
Drug: Low-dose DOAC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose DOAC use
Trial: 38842520
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a alone (180 μg per week for 48 weeks)
Trial: 38842520
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg bulevirtide plus peginterferon alfa-2a (180 μg per week for 48 weeks)
Trial: 38842520
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bulevirtide plus peginterferon alfa-2a (180 μg per week for 48 weeks)
Trial: 38842520
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bulevirtide monotherapy (for 96 weeks)
Trial: 38842606
Drug: Neoadjuvant-adjuvant anti-PD1
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neoadjuvant-adjuvant anti-PD1 therapy
Trial: 38842606
Drug: Adjuvant anti-PD-1
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant anti-PD-1 therapy
Trial: 38842606
Drug: Tailored approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored approach to surgery and adjuvant therapy based on response to initial neoadjuvant immunotherapy
Trial: 38842738
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied on days 0, 3, 7, and 14 after extraction, repeated biweekly until the end of retraction.
Trial: 38842764
Drug: Dexketoprofen 25
RxNorm normalized name: dexketoprofen 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen 25 mg/vitamin B (thiamine 100 mg, pyridoxine 50 mg, cyanocobalamin 0.50 mg) in a fixed-dose combination (FDC)
Trial: 38842764
Drug: Dexketoprofen 25
RxNorm normalized name: dexketoprofen 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen 25 mg monotherapy
Trial: 38842764
Drug: Dexketoprofen monotherapy
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen monotherapy
Trial: 38842838
Drug: Neoadjuvant nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant nivolumab plus chemotherapy (nab-paclitaxel and carboplatin) followed by response-adapted locoregional therapy (LRT)
Trial: 38842838
Drug: Response-adapted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response-adapted therapy (group A: single-modality radiotherapy or transoral robotic surgery; group B: intermediate-dose chemoradiotherapy; group C: regular-dose chemoradiotherapy)
Trial: 38842838
Drug: Neoadjuvant nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant nivolumab and chemotherapy followed by response-adapted LRT
Trial: 38842850
Drug: mHealth intervention
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth intervention (cognitive behavior therapy for psychosis strategies)
Trial: 38843038
Drug: Clusters based
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clusters based on within-treatment symptom trajectories